C12N 2760/18121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/18121 (Viruses as such) appears on 22 US grants and 44 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 44
- Assignees
- 25
- Inventors
- 109
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 2 |
| 2013 | 3 | 0 |
| 2014 | 0 | 6 |
| 2015 | 3 | 0 |
| 2016 | 1 | 2 |
| 2017 | 1 | 4 |
| 2018 | 3 | 4 |
| 2019 | 4 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 3 | 7 |
| 2023 | 0 | 4 |
| 2024 | 2 | 3 |
| 2025 | 0 | 3 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant herpesvirus of turkeys (HVT) and preparation method and use thereof6 Jan 2026US 12,516,353 B2Yangzhou University
- Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof30 Jan 2024US 11,883,481 B2Zoetis Services LLC
- Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same30 Jan 2024US 11,884,931 B2Libentech Co., Ltd.
- Paramyxovirus vaccine strain for novel coronavirus pneumonia and construction method thereof1 Nov 2022US 11,484,588 B1Qingdao Harwars Biology Group Ltd.
- Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof11 Oct 2022US 11,464,849 B2Zoetis Services LLC
- Apmv and uses thereof for the treatment of cancer30 Jul 2026US 2026/0216266 A1Icahn School of Medicine at Mount Sinai
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Newcastle Disease Virus with Improved Heat Resistance, and Newcastle Disease Virus Vaccine Comprising Same5 Mar 2026US 2026/0061047 A1Biopoa, Inc.
- Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity11 Dec 2025US 2025/0375515 A1Consejo Nacional De Humanidades, Ciencias Y TecnologíAS
- Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof7 Aug 2025US 2025/0250304 A1Bernhard-Nocht-Institut FüR Tropenmedizin
Most cited
By later US patents
- Chimeric Newcastle disease viruses and uses thereof10US 8,591,881 B2Memorial Sloan Kettering Cancer Center · 2013
- Chimeric viruses presenting non-native surface proteins and uses thereof8US 9,387,242 B2Icahn School of Medicine at Mount Sinai · 2016
- Chimeric Newcastle disease viruses and uses thereof7US 9,217,136 B2Icahn School of Medicine at Mount Sinai · 2015
- Newcastle disease viruses and uses thereof4US 10,251,922 B2Icahn School of Medicine at Mount Sinai · 2019
- Chimeric viruses presenting non-native surface proteins and uses thereof3US 10,308,913 B2Icahn School of Medicine at Mount Sinai · 2019